Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

ed with an increase in journal advertising and web-based promotion.

Interest expense on the Company's convertible notes was $4.9 million for the three months ended June 30, 2011, comprised of $2.7 million of interest expense and $2.2 million of non-cash amortization expense.  Interest expense was $8.0 million for the six months ended June 30, 2011, comprised of $4.4 million of interest expense and $3.6 million of non-cash amortization expense.

Conference CallSavient's management team will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on August 4, 2011, to discuss these results and to answer questions.

To participate by telephone, please dial 877-278-8171 (Domestic) or 574-941-7303 (International). The conference ID number is 84217509.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on August 4, 2011, through 12:00 a.m. Eastern Time on August 14, 2011, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 84217509.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
2. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
3. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
4. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
5. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
6. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
7. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
8. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
10. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
11. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... is investigating potential claims on behalf of purchasers ... or the "Company") (NasdaqGS: AMAG -News).  The investigation ... violated federal securities laws. On May ... 10.73% during intraday trading after the company announced ...
(Date:5/22/2013)... CAESAREA, Israel , May 22, 2013 /PRNewswire/ ... data presented from the DEFLECT-I study demonstrates that Keystone ... lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures ... Scientific Advisory Board announces consensus on the importance of ... importance and need for cerebral protection during cardiovascular procedures ...
(Date:5/22/2013)... 2013  Healthcare providers are turning to ... (ECM) solution, for a deeper ...  These organizations identified enterprise content management as ... OnBase to optimize their Meditech system and ... (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO  ) These ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3
... Oct. 14, 2011 EMKinetics, Inc. announced today ... pivotal trial for patients suffering from urge ... be conducted at 10-15 US centers.  Submission for ... completion of the study.   EMKinetics, TranStim therapy ...
... Hearing Institute (BHI) is warning consumers of the ... instead of consulting a hearing healthcare professional. Hearing loss ... problem. All 50 states require that consumers use a ... BHI also points out that hearing devices that ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Better Hearing Institute Warns on Do-It-Yourself Hearing Care 2Better Hearing Institute Warns on Do-It-Yourself Hearing Care 3
(Date:5/22/2013)... Zensah® Compression Apparel released a statement ... titled "Breast pain while running affects one-third of ... help." According to the article, a British study surveyed ... suffer from breast pain while running but do not ... , Zensah emphasizes the importance for women to ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... more likely to attempt suicide, whether or not they ... to a new study. "Clinicians who are seeing ... are at increased risk of suicide," said study co-author ... Treatment Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... York, New York (PRWEB) May 22, 2013 ... metal-on-metal version of the DePuy Pinnacle Hip Replacement System ... in Texas Federal Court, Bernstein Liebhard LLP reports. ... has directed DePuy Orthopaedics to produce monitoring reports associated ... into the company’s medical device marketing practices. Plaintiffs ...
(Date:5/22/2013)... 22, 2013 According to a May 14, ... More Options for Breast Cancer Surgery,” modern medical technology has ... approach this disease in a whole new light. Since the ... now face breast cancer and mastectomies with greater ... “Before the introduction of plastic surgery to oncology, women had ...
(Date:5/22/2013)... Michigan study challenges previous research that suggests umpire ... study, a collaboration between researchers at U-M and ... into the controversial argument over whether MLB umpires ... of the same race. It found little statistical ... associate professor of sport management at the U-M ...
Breaking Medicine News(10 mins):Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 3Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2
... Hospital along with Northwestern University Feinberg School of Medicine ... if avastin is effective in pancreatic tumours.// ,The ... that is designed to inhibit the growth of blood ... to see that it in combination with abdominal radiation ...
... ripple effect caused by the bird flu threat has resulted ... in the Indian capital. One can see that in Gazipur ... kg. // ,Only those chickens that were certified ... sold for Rs.20-25, whereas those that were uncertified was available ...
... vaccine, Gardasil is expected to be launched in New ... of age. // Soon, men might also be given ... sexual partners and to protect themselves against several diseases. ... phase, for demonstration of cervical cancer prevention. Most cases ...
... European Union has a huge health problem of having ... ailment in the Union, that costed the bloc’s members, a ... // ,Take a look at the annual ... disease ruled, making a dent of 230 euros on an ...
... or the sex determination gene, that plays a crucial role ... or female (embryo with SRY gene develops into a male), ... // The SRY protein, required for formation of testes is ... researchers from Prince Henry's Institute and University of California. ...
... National Institutes of Health (NIH) said that Heart health ... such as exercise, learning new// things and staying socially ... & Dementia. ,William Thies, PhD, vice ... said that specific combinations of lifestyle choices, and also ...
Cached Medicine News:Health News:Avastin under trial to test efficacy for pancreatic tumours! 2Health News:Delhi Sees Sharp Decline In Chicken Prices 2Health News:Delhi Sees Sharp Decline In Chicken Prices 3Health News:Men Might Get Their Share of Cervical Cancer Vaccine As Well 2Health News:Sex Determination Gene Blamed For High Incidence Of Parkinson’s In Me 2Health News:Cognitive deterioration in the older generation can be prevented by modifying the lifestyle 2
... The Hudson RCI ... a patented "split prong" ... oxygen supply tubes with ... provides the utmost control ...
... equivalent of 7.5 liters out of your five-liter ... two machines for your high-flow patients! , ... Devices function like standard conservers, because they extend ... required to saturate a patient. However, they ...
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Medicine Products: